Suscribirse

The MBOAT7 rs641738 variant is associated with an improved outcome in primary sclerosing cholangitis - 11/10/20

Doi : 10.1016/j.clinre.2019.12.006 
Cora Freund a , Arne Wahlers a , Nima Haji Begli a , Yvonne Leopold a , Petra Klöters-Plachky a , Arianeb Mehrabi b , Isabelle Mohr a , Julia Sander a , Christian Rupp a , Daniel Nils Gotthardt a, c , Karl Heinz Weiss a,
a Department of Internal Medicine IV, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany 
b Department of General, Visceral and Transplantation Surgery, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany 
c Mediteo GmbH, Hauptstraße 90, 69117 Heidelberg, Germany 

Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

páginas 7
Iconografías 5
Vídeos 0
Otros 0

Highlights

Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease that causes liver cirrhosis, leading to liver failure.
The sole curative option for PSC to date is liver transplantation.
The membrane bound O-acyltransferase domain containing 7 (MBOAT7) rs641738 and rs626283 variant alleles have been associated with both an accelerated progression of the disease and a higher risk for developing a more severe phenotype in many chronic hepatic diseases.
Thus, we analysed their effect on long-term outcomes in PSC patients.
We found that transplant-free survival was significantly prolonged – not reduced – in carriers of two rs641738 variant alleles, which was referred to as the TT genotype (mean 19.6 years; 95% confidence interval [CI]: 16.3–22.9 years) compared to the CC (mean 15.4 years, 95% CI 12.8–18.0 years) and heterozygous genotypes (mean 13.2 years, 95% CI 11.4–15.0 years) (P=0.017).
This study could help improve individual prognosis in PSC patients and give some new perspective on the involvement of the immune system in PSC.

El texto completo de este artículo está disponible en PDF.

Summary

Background and aims

Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease that causes liver cirrhosis, leading to liver failure. Additionally, PSC is a risk factor for cholangiocarcinoma. Its mechanism is unknown, and liver transplantation remains the sole curative option. The membrane bound O-acyltransferase domain containing 7 (MBOAT7) rs641738 and rs626283 variant alleles have been associated with both an accelerated progression of the disease and a higher risk for developing a more severe phenotype in many chronic hepatic diseases. Thus, we analysed their effect on long-term outcomes and laboratory parameters in PSC patients.

Methods

We determined MBOAT7 genotypes and estimated the actuarial survival rate free of liver transplantation, using the Kaplan-Meier estimator. The differences between the estimates were analysed using the log-rank test. Patient blood was drawn and analysed for different serum parameters including cholestatic markers. Additionally, MBOAT7 RNA expression in human hepatic cell lines MZCHA1 (a biliary adenocarcinoma cell line), HepG2 (a hepatocellular carcinoma cell line), LX-2 (hepatic stellate cell line) and H-69 (cholangiocyte cell line) was analysed.

Results

Transplant-free survival was significantly prolonged in carriers of two rs641738 variant alleles, which was referred to as the TT genotype (mean 19.6 years; 95% confidence interval [CI]: 16.3–22.9 years) compared to the CC (mean 15.4 years, 95% CI 12.8–18.0 years) and heterozygous genotypes (mean 13.2 years, 95% CI 11.4–15.0 years) (P=0.017). This effect was restricted to male patients. We confirmed the high expression of MBOAT7 in hepatic stellate cells and found that MBOAT7 is less expressed in biliary epithelial cell lines, compared to parenchymal hepatic cells.

Conclusions

Unlike other chronic liver diseases, carrying two MBOAT7 variant alleles does not seem to affect PSC patients negatively, but seems to have a positive effect on transplant-free survival. This study could help improve individual prognosis in PSC patients and give some new perspective on the involvement of the immune system in PSC.

El texto completo de este artículo está disponible en PDF.

Keywords : Primary sclerosing cholangitis, Membrane bound O-acyltransferase domain containing 7 gene, Hepatic fibrosis, Hepatic stellate cells

Abbreviations : PSC, MBOAT7, NAFLD


Esquema


© 2019  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 44 - N° 5

P. 646-652 - octobre 2020 Regresar al número
Artículo precedente Artículo precedente
  • Surgical management of oligometastatic disease in gastric cancer
  • Peng Jin, Xiaoyan Ji, Yantao Tian
| Artículo siguiente Artículo siguiente
  • The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: A systematic review and meta-analysis
  • Haizhou Wang, Peishan Qiu, Jing Liu, Fan Wang, Qiu Zhao

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.